tiprankstipranks
Trending News
More News >
Orasure Technologies (OSUR)
NASDAQ:OSUR
Advertisement

Orasure Technologies (OSUR) Price & Analysis

Compare
642 Followers

OSUR Stock Chart & Stats


Orasure Technologies News

OSUR FAQ

What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.36 and its highest was $4.61 in the past 12 months.
    What is Orasure Technologies’s market cap?
    Orasure Technologies’s market cap is $254.52M.
      When is Orasure Technologies’s upcoming earnings report date?
      Orasure Technologies’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.
        How were Orasure Technologies’s earnings last quarter?
        Orasure Technologies released its earnings results on Aug 05, 2025. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$0.055.
          Is Orasure Technologies overvalued?
          According to Wall Street analysts Orasure Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Orasure Technologies pay dividends?
            Orasure Technologies does not currently pay dividends.
            What is Orasure Technologies’s EPS estimate?
            Orasure Technologies’s EPS estimate is -0.19.
              How many shares outstanding does Orasure Technologies have?
              Orasure Technologies has 73,136,986 shares outstanding.
                What happened to Orasure Technologies’s price movement after its last earnings report?
                Orasure Technologies reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went down -8.333%.
                  Which hedge fund is a major shareholder of Orasure Technologies?
                  Currently, no hedge funds are holding shares in OSUR

                  Company Description

                  Orasure Technologies

                  Orasure Technologies, Inc. is a leading provider of oral fluid diagnostic products, specializing in the development, manufacture, and marketing of innovative medical devices and testing solutions. The company primarily operates in the healthcare sector, focusing on infectious disease testing, drug testing, and molecular diagnostics. Its core products include the OraQuick® rapid HIV test and the Intercept® oral fluid collection device, which are designed for ease of use and accuracy in various clinical and non-clinical settings.

                  Orasure Technologies (OSUR) Earnings & Revenues

                  OSUR Earnings Call

                  Q2 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call presented several highlights, including the successful launch of the HEMAcollect PROTEIN product and a strong cash position. However, these were offset by significant challenges, such as disruptions in international diagnostics and a decline in Sample Management revenue. The uncertainty in U.S. Diagnostics further balanced the positive developments.View all OSUR earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Pro-Dex
                  Stereotaxis
                  Utah Medical Products
                  REPRO-MED Systems
                  Sanara MedTech

                  Ownership Overview

                  4.82%19.25%29.82%32.79%
                  29.82% Other Institutional Investors
                  32.79% Public Companies and
                  Individual Investors
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis